GSK Reports Strong 2025 Financial Growth, 5 Major FDA Approvals, and Increased Dividends
Summary
GSK plc reported strong 2025 financial results with significant profit and EPS growth, driven by Specialty Medicines and five major FDA approvals. The company also announced increased dividends and a substantial share buyback program, alongside a CEO transition and strategic focus on R&D and technology.
Key Events
-
Strong 2025 Financial Performance
GSK reported a 7% CER increase in turnover, over 100% CER growth in operating profit, and over 100% CER growth in total earnings per share for 2025, primarily driven by its Specialty Medicines segment.
-
Five Major FDA Product Approvals
The company secured five significant FDA approvals in 2025 for Exdensur (severe asthma), Blenrep (multiple myeloma), Nucala (COPD), Blujepa (uUTI/gonorrhoea), and Penmenvy (meningitis vaccine).
-
Increased Shareholder Returns
GSK declared a 66p dividend per share for 2025, up from 61p in 2024, and projected 70p for 2026. The company also executed £1.377 billion of its £2 billion share buyback program by year-end 2025.
-
Strategic Pipeline Advancement and Acquisitions
The R&D pipeline saw 17 assets in Phase III and 7 pivotal trial starts, with strategic acquisitions like IDRx and Empirico strengthening key therapeutic areas. However, some R&D programs were discontinued due to efficacy criteria.
Analysis
GSK's 2025 annual report showcases a robust year, with significant growth in operating profit and earnings per share, reflecting strong performance in its Specialty Medicines portfolio. The company's R&D efforts yielded five major FDA approvals and advanced numerous pipeline assets, signaling future growth potential. A notable increase in dividends for 2025 and a positive outlook for 2026, coupled with a substantial share buyback program, underscore management's confidence and commitment to shareholder returns. The transition to a new CEO, Luke Miels, with a clear strategic focus on R&D acceleration and technology adoption, positions GSK for continued momentum.
At the time of this filing, GSK was trading at $54.41 on NYSE in the Life Sciences sector, with a market capitalization of approximately $111.1B. The 52-week trading range was $32.38 to $61.70. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.